Systemic lupus erythematosus in women: Impact on family size

Arthritis Care and Research

Volumn 59, Issue 11, 2008, Pages 1656-1660

  Vinet, Evelyne ^a   Pineau, Christian ^a   Gordon, Caroline ^b   Clarke, Ann E ^a   Bernatsky, Sasha ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; DICLOFENAC; GONADORELIN; INDOMETACIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ANOVULATION; CLEFT LIP; CLEFT PALATE; CONGENITAL MALFORMATION; FAMILY SIZE; FERTILITY; GONADAL DISEASE; HUMAN; HYPERTELORISM; INFERTILITY; MENSTRUAL IRREGULARITY; MICROGNATHIA; NONHUMAN; PREGNANCY; PREMATURE OVARIAN FAILURE; REVIEW; SEXUALITY; SYSTEMIC LUPUS ERYTHEMATOSUS;

FAMILY CHARACTERISTICS; FEMALE; FERTILITY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; SEXUALITY;

EID: 56049120787     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.24203     Document Type: Review

References (63)

1. Hardy CJ, Palmer BP, Morton SJ, Muir KR, Powell RJ. Pregnancy outcome and family size in systemic lupus erythematosus: a case-control study. Rheumatology (Oxford) 1999;38:559-63.
2. Skomsvoll JF, Ostensen M, Baste V, Irgens LM. Number of births, interpregnancy interval, and subsequent pregnancy rate after a diagnosis of inflammatory rheumatic disease in Norwegian women. J Rheumatol 2001;28:2310-4.
3. Fraga A, Mintz G, Orozco H. Fertility rates, fetal wastage and maternal morbidity in SLE. J Rheumatol 1974;1:293-8.
4. Katz PP. Childbearing decisions and family size among women with rheumatoid arthritis. Arthritis Rheum 2006;55:217-23.
5. Lockshin MD. Pregnancy does not cause systemic lupus erythematosus to worsen. Arthritis Rheum 1989;32:665-70.
6. Meehan RT, Dorsey JK. Pregnancy among patients with systemic lupus erythematosus receiving immunosuppressive therapy. J Rheumatol 1987;14:252-8.
7. Urowitz MB, Gladman DD, Farewell VT, Stuart J, McDonald J. Lupus and pregnancy studies. Arthritis Rheum 1993;36:1392-7.
8. Tincani A, Faden D, Tarantini M, Lojacono A, Tanzi P, Gastaldi A, et al. Systemic lupus erythematosus and pregnancy: a prospective study. Clin Exp Rheumatol 1992;10:439-46.
9. Petri M. Hopkins Lupus Pregnancy Center: 1987 to 1996. Rheum Dis Clin North Am 1997;23:1-13.
10. Lima F, Buchanan NM, Khamashta MA, Kerslake S, Hughes GR. Obstetric outcome in systemic lupus erythematosus. Semin Arthritis Rheum 1995;25:184-92.
11. Carmona F, Font J, Cervera R, Munoz F, Cararach V, Balasch J. Obstetrical outcome of pregnancy in patients with systemic lupus erythematosus: a study of 60 cases. Eur J Obstet Gynecol Reprod Biol 1999;83:137-42.
12. Cortes-Hernandez J, Ordi-Ros J, Paredes F, Casellas M, Castillo F, Vilardell-Tarres M. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology (Oxford) 2002;41:643-50.
13. Chakravarty EF, Colon I, Langen ES, Nix DA, El-Sayed YY, Genovese MC, et al. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. Am J Obstet Gynecol 2005;192:1897-904.
14. Rubbert A, Pirner K, Wildt L, Kalden JR, Manger B. Pregnancy course and complications in patients with systemic lupus erythematosus. Am J Reprod Immunol 1992;28:205-7.
15. Clowse ME, Magder LS, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 2005;52:514-21.
16. Clowse ME, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006;54:3640-7.
17. Costedoat-Chalumeau N, Amoura Z, Duhaut P, Huong DL, Sebbough D, Wechsler B, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2003;48:3207-11.
18. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991;324:150-4.
19. Ostensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H, et al. Anti-inflammatory and immunosuppressive drugs and reproduction [review]. Arthritis Res Ther 2006;8:209.
20. Clowse ME. Lupus activity in pregnancy. Rheum Dis Clin North Am 2007;33:237-52.
21. Clark CA, Spitzer KA, Nadler JN, Laskin CA. Preterm deliveries in women with systemic lupus erythematosus. J Rheumatol 2003;30:2127-32.
22. Moroni G, Ponticelli C. The risk of pregnancy in patients with lupus nephritis. J Nephrol 2003;16:161-7.
23. Qazi UM, Petri M. Autoantibodies, low complement and obesity predict pre-eclampsia in SLE: a case-control study [abstract]. Arthritis Rheum 2006;54Suppl9:S264.
24. Petri M. Immunosuppressive drug use in pregnancy. Autoimmunity 2003;36:51-6.
25. Perez-Aytes A, Ledo A, Boso V, Saenz P, Roma E, Poveda JL, et al. In utero exposure to mycophenolate mofetil: a characteristic phenotype? Am J Med Genet A 2008;146:1-7.
26. Velinov M, Zellers N. The fetal mycophenolate mofetil syndrome. Clin Dysmorphol 2008;17:77-8.
27. Schoner K, Steinhard J, Figiel J, Rehder H. Severe facial clefts in acrofacial dysostosis: a consequence of prenatal exposure to mycophenolate mofetil? Obstet Gynecol 2008;111:483-6.
28. Sifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz MJ, Armenti VT. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 2006;82:1698-702.
29. Murashima A, Fukazawa T, Hirashima M, Takasaki Y, Oonishi M, Niijima S, et al. Long term prognosis of children born to lupus patients. Ann Rheum Dis 2004;63:50-3.
30. Stein H, Walters K, Dillon A, Schulzer M. Systemic lupus erythematosus: a medical and social profile. J Rheumatol 1986;13:570-6.
31. Huang CM, Yang YH, Chiang BL. Different familial association patterns of autoimmune diseases between juvenile-onset systemic lupus erythematosus and juvenile rheumatoid arthritis. J Microbiol Immunol Infect 2004;37:88-94.
32. Yasmeen S, Wilkins EE, Field NT, Sheikh RA, Gilbert WM. Pregnancy outcomes in women with systemic lupus erythematosus. J Matern Fetal Med 2001;10:91-6.
33. Wen SW, Smith G, Yang Q, Walker M. Epidemiology of preterm birth and neonatal outcome. Semin Fetal Neonatal Med 2004;9:429-35.
34. Keijzer-Veen MG, Finken MJ, Nauta J, Dekker FW, Hille ET, Frolich M, et al. Is blood pressure increased 19 years after intrauterine growth restriction and preterm birth? A prospective follow-up study in the Netherlands. Pediatrics 2005;116:725-31.
35. Rossi P, Tauzin L, Marchand E, Simconi U, Frances Y. Arterial blood pressure and arterial stiffness in adolescents are related to gestational age. Arch Mal Coeur Vaiss 2006;99:748-51. In French.
36. Hofman PL, Cutfield WS. Insulin sensitivity in people born pre-term, with low or very low birth weight and small for gestational age. J Endocrinol Invest 2006;29:2-8.
37. Barker DJ. Fetal origins of coronary heart disease. BMJ 1995;311:171-4.
38. Neri F, Chimini L, Filippini E, Motta M, Faden D, Tincani A. Pregnancy in patients with rheumatic diseases: psychological implication of a chronic disease and neuropsychological evaluation of the children. Lupus 2004;13:666-8.
39. Neri F, Chimini L, Bonomi F, Filippini E, Motta M, Faden D, et al. Neuropsychological development of children born to patients with systemic lupus erythematosus. Lupus 2004;13:805-11.
40. Ross G, Sammaritano L, Nass R, Lockshin M. Effects of mothers' autoimmune disease during pregnancy on learning disabilities and hand preference in their children. Arch Pediatr Adolesc Med 2003;157:397-402.
41. Lahita RG. Systemic lupus erythematosus: learning disability in the male offspring of female patients and relationship to laterality. Psychoneuroendocrinology 1988;13:385-96.
42. Curry SL, Levine SB, Corty E, Jones PK, Kurit DM. The impact of systemic lupus erythematosus on women's sexual functioning. J Rheumatol 1994;21:2254-60.
43. Ostensen M. New insights into sexual functioning and fertility in rheumatic diseases. Best Pract Res Clin Rheumatol 2004;18:219-32.
44. Panush RS, Mihailescu GD, Gornisiewicz MT, Sutaria SH. Sex and arthritis. Bull Rheum Dis 2000;49:1-4.
45. Boomsma MM, Bijl M, Stegeman CA, Kallenberg CG, Hoffman GS, Tervaert JW. Patients' perceptions of the effects of systemic lupus erythematosus on health, function, income, and interpersonal relationships: a comparison with Wegener's granulomatosis. Arthritis Rheum 2002;47:196-201.
46. McElhone K, Abbott J, Shelmerdine J, Bruce IN, Ahmad Y, Gordon C, et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQoL, for adults with systemic lupus erythematosus. Arthritis Rheum 2007;57:972-9.
47. Hill J, Bird H, Thorpe R. Effects of rheumatoid arthritis on sexual activity and relationships. Rheumatology (Oxford) 2003;42:280-6.
48. Kraaimaat FW, Bakker AH, Janssen E, Bijlsma JW. Intrusiveness of rheumatoid arthritis on sexuality in male and female patients living with a spouse. Arthritis Care Res 1996;9:120-5.
49. Gleicher N. Antiphospholipid antibodies and reproductive failure: what they do and what they don't do; how to, and how not to treat! Hum Reprod 1997;12:13-6.
50. Ghazeeri GS, Kutteh WH. Autoimmune factors in reproductive failure. Curr Opin Obstet Gynecol 2001;13:287-91.
51. Practice Committee of the American Society for Reproductive Medicine. Anti-phospholipid antibodies do not affect IVF success. Fertil Steril 2006;86:S224-5.
52. Hornstein MD, Davis OK, Massey JB, Paulson RJ, Collins JA. Antiphospholipid antibodies and in vitro fertilization success: a meta-analysis. Fertil Steril 2000;73:330-3.
53. Mendonca LL, Khamashta MA, Nelson-Piercy C, Hunt BJ, Hughes GR. Non-steroidal anti-inflammatory drugs as a possible cause for reversible infertility. Rheumatology (Oxford) 2000;39:880-2.
54. Sookvanichsilp N, Pulbutr P. Anti-implantation effects of indomethacin and celecoxib in rats. Contraception 2002;65:373-8.
55. Pall M, Friden BE, Brannstrom M. Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double blind study. Hum Reprod 2001;16:1323-8.
56. Gayed M, Gordon C. Pregnancy and rheumatic diseases. Rheumatology (Oxford) 2007;46:1634-40.
57. Boumpas DT, Austin HA III, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993;119:366-9.
58. Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 2005;52:2761-7.
59. Pasoto SG, Mendonca BB, Bonfa E. Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: clinical, hormonal and therapeutic associations. Lupus 2002;11:175-80.
60. Kong NC. Pregnancy of a lupus patient: a challenge to the nephrologist. Nephrol Dial Transplant 2006;21:268-72.
61. Canada's National Statistical Agency. Fertility. 2008. URL: http://www.statcan.ca/english/concepts/definitions/fertility.htm.
62. Lobo RA. Chapter 41: Infertility, diagnostic evaluation, management, prognosis. In: Katz VL, Lobo RA, Lentz G, Gershenson D, editors. Comprehensive gynecology. 5th ed. Philadelphia: Mosby; 2007.
63. Rogers M. Psychologic aspects of pregnancy in patients with rheumatic diseases. Rheum Dis Clin North Am 1989;15:361-74.